Biomaterials for Orbit Reconstruction

描述(来自申请人的逐字)：我们将开发仿生材料 眼眶及周围骨性结构的修复和整形。这些 支架将包含一种与胶原蛋白相关的细胞结合肽 将使它们成为细胞的胶原样锚定。这些胶原蛋白 替代基质(CSM)将促进细胞从 宿主组织，促进3-D克隆形成，它们将提供一种允许 细胞分化和组织重塑的环境。在第一阶段研究中， 我们将(1)定量检查细菌的黏附、迁移和定植 成骨细胞样细胞系的CSM，(2)细胞形态特征 用组织学和电子显微镜方法测定菌落，(3)确定 不同生长因子对细胞黏附、增殖和生长的影响 细胞在合成支架上的分化，以及(4)检测表达 骨特异性分子(I型胶原、碱性磷酸酶、骨联素、 骨钙素)和生长因子(转化生长因子β1、骨形态发生蛋白2、4、6和7)。在……里面 第二阶段，我们将检查这些基质作为动物移植物的性能。 模型作为组织中的空间填充物。CSM对组织也很有用 隆起和组织工程学。 建议的商业应用： 修复骨性眼眶和周围的颅面部骨骼结构需要生物材料。这种材料也可以用于其他地方的骨骼修复。用于整形外科移植物和植入物的生物材料的整体市场价值估计以数十亿美元计。

DESCRIPTION (Verbatim from Applicant): We will develop biomimetic materials for repair and orthoplasty of the orbit and surrounding bony structures. These scaffolds will incorporate a cell binding peptide related to collagen which will allow them to serve as collagen-like anchorages for cells. These Collagen Surrogate Matrices (CSM) will facilitate haptotactic migration of cells from host tissue, promote 3-D colony formation, and they will provide a permissive environment for cell differentiation and tissue remodeling. In Phase I studies, we will (1) examine quantitatively the adhesion, migration, and colonization of CSM by osteoblast-like cell lines, (2) characterize the morphology of cellular colonies using histological and electron microscopic procedures, (3) determine the effect of various growth factors on the attachment, proliferation, and differentiation of cells on synthetic scaffolds, and (4) examine the expression of bone-specific molecules (type I collagen, alkaline phosphatase, osteonectin, osteocalcin), and growth factors (TGF-B1, BMPs 2, 4, 6 and 7) using PCR. In Phase II we will examine the performance of these matrices as grafts in animal models as space fillers in tissues. CSM will be also useful for tissue augmentation and tissue engineering. PROPOSED COMMERCIAL APPLICATIONS: There is a major need for biomaterials for repair of the bony orbit and surrounding cranio-facial skeletal structures. Such materials can also be useful for repair of bone elsewhere. The overall market value of biomaterials for orthopedic grafts and implants is estimated to be in billions of dollars.